Noël G, Feuvret L, Bourhis J, Pousset F, Gerbaulet A, Popowski Y, Mazeron J J
Centre des tumeurs, hôpital de la Pitié-Salpêtrière, Paris, France.
Cancer Radiother. 1998 Jul-Aug;2(4):325-37. doi: 10.1016/s1278-3218(98)80344-2.
About 30% of patients who underwent percutaneous transluminal coronary angioplasty show evidence of restenosis, which appears to be independent of the angioplasty method used. The restenosis is due of two factors, firstly migration of smooth vascular muscle cells of the vascular media to the intima and multiplication which lead to the formation of a neo-intima. Irradiation limits the proliferation by acting of the cells in the mitotic stage. The vascular target volume is not very thick and is difficult to define it, that why brachytherapy seems to be the best procedure to prevent restenosis. However, the development of this treatment present many difficulties. Different irradiation techniques have been studied. Such techniques include catheter containing radioactive sealed source, radioactive stent, or balloon containing radioactive liquid inside. Each of these methods have their own advantages, inconveniences, problems and risks. Radioisotope may be either beta or gamma emitters. Gamma emitter presents problems for radioprotection but the satisfactory dose distribution may be difficult to obtain using beta emitter. Choice of dose, dose rate and delay between the end of angioplasty and the beginning of brachytherapy is subject to some discuss. Animal experiments using radioisotope have shown reduction in cell proliferation. Human trials showed feasibility, safety of the method and real impact on restenosis prevention. However, long-term efficacy has not been proved because the follow-up of the patients is too short. A randomized trial of 192Ir brachytherapy for prevention of restenosis has recently shown the efficacy in short and median term. However, long term efficiency and secondary effects have not yet been established as the follow up time of this study is still too short. That is why, collaboration between cardiologists and radiotherapists and physicists is indispensable to enable the development of an optimal technique.
接受经皮腔内冠状动脉成形术的患者中,约30%出现再狭窄迹象,这似乎与所使用的血管成形术方法无关。再狭窄归因于两个因素,首先是血管中膜的平滑肌细胞迁移至内膜并增殖,从而导致新生内膜的形成。辐射通过作用于处于有丝分裂阶段的细胞来限制增殖。血管靶体积不是很厚且难以界定,这就是为什么近距离放射治疗似乎是预防再狭窄的最佳方法。然而,这种治疗方法的发展存在许多困难。已经研究了不同的放射技术。这些技术包括含有放射性密封源的导管、放射性支架或内部含有放射性液体的球囊。这些方法中的每一种都有其自身的优点、不便之处、问题和风险。放射性同位素可以是β射线发射体或γ射线发射体。γ射线发射体存在辐射防护问题,但使用β射线发射体可能难以获得令人满意的剂量分布。血管成形术结束与近距离放射治疗开始之间的剂量、剂量率和延迟的选择存在一些争议。使用放射性同位素的动物实验表明细胞增殖减少。人体试验表明了该方法的可行性、安全性以及对预防再狭窄的实际影响。然而,由于患者随访时间过短,长期疗效尚未得到证实。一项关于192Ir近距离放射治疗预防再狭窄的随机试验最近显示了短期和中期的疗效。然而,由于这项研究的随访时间仍然过短,长期疗效和副作用尚未确定。这就是为什么心脏病专家、放射肿瘤学家和物理学家之间的合作对于开发最佳技术是必不可少的。